Repeatability and reproducibility of a handheld quantitative G6PD diagnostic

• Main Authors: Benedikt Ley, Ari Winasti Satyagraha, Mohammad Golam Kibria, Jillian Armstrong, Germana Bancone, Amy K. Bei, Greg Bizilj, Marcelo Brito, Xavier C. Ding, Gonzalo J. Domingo, Michael E. von Fricken, Gornpan Gornsawun, Brandon Lam, Didier Menard, Wuelton Monteiro, Stefano Ongarello, Sampa Pal, Lydia Visita Panggalo, Sunil Parikh, Daniel A. Pfeffer, Ric N. Price, Alessandra da Silva Orfano, Martina Wade, Mariusz Wojnarski, Kuntawunginn Worachet, Aqsa Yar, Mohammad Shafiul Alam, Rosalind E. Howes
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2022
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Public aspects of medicine; RA1-1270; Arctic
• Online Access: https://doaj.org/article/642a94882b9840718bf43f3aab3c7603

Background The introduction of novel short course treatment regimens for the radical cure of Plasmodium vivax requires reliable point-of-care diagnosis that can identify glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. While deficient males can be identified using a qualitative diagnostic test, the genetic make-up of females requires a quantitative measurement. SD Biosensor (Republic of Korea) has developed a handheld quantitative G6PD diagnostic (STANDARD G6PD test), that has approximately 90% accuracy in field studies for identifying individuals with intermediate or severe deficiency. The device can only be considered for routine care if precision of the assay is high. Methods and findings Commercial lyophilised controls (ACS Analytics, USA) with high, intermediate, and low G6PD activities were assessed 20 times on 10 Biosensor devices and compared to spectrophotometry (Pointe Scientific, USA). Each device was then dispatched to one of 10 different laboratories with a standard set of the controls. Each control was tested 40 times at each laboratory by a single user and compared to spectrophotometry results. When tested at one site, the mean coefficient of variation (CV) was 0.111, 0.172 and 0.260 for high, intermediate, and low controls across all devices respectively; combined G6PD Biosensor readings correlated well with spectrophotometry (rs = 0.859, p<0.001). When tested in different laboratories, correlation was lower (rs = 0.604, p<0.001) and G6PD activity determined by Biosensor for the low and intermediate controls overlapped. The use of lyophilised human blood samples rather than fresh blood may have affected these findings. Biosensor G6PD readings between sites did not differ significantly (p = 0.436), whereas spectrophotometry readings differed markedly between sites (p<0.001). Conclusions Repeatability and inter-laboratory reproducibility of the Biosensor were good; though the device did not reliably discriminate between intermediate and low G6PD activities of the lyophilized ...